Biotech Co.* |
Pharma Co. |
Type/Product Area | Terms/Details (Date) |
Affectis |
NV Organon (the Netherlands) |
Affectis will apply its technologies to the validation of gene targets in depression and anxiety |
Terms of the deal were not disclosed (11/2) |
Affibody AB* |
Asahi Kasei Corp. (Japan) |
Affibody will develop a product for the removal of a target molecule from fluid mixtures |
Asahi Kasei intends to develop a medical device using the Affibody molecule; terms of the deal were not disclosed (11/1) |
Affymetrix |
Applied Biosystems Group |
ABG got nonexclusive rights to patents related to the use and sale of microarrays for gene expression analysis |
The license will be applied to the expansion of the Applied Biosystems Expression Array System; terms were not disclosed (12/22) |
Albany |
Bristol-Myers Squibb Co. |
BMS got rights to compounds that encompass biogenic amine reuptake inhibitors for treating depression and other CNS disorders |
AMRI gets an up-front payment of $8M and $10M in research funding over three years; it also is eligible to receive up to $66M per compound in development and regulatory milestone payments for the first two com- pounds and milestone payments of up to $22M for subsequent compounds, as well as royalties on resulting sales (10/24) |
Alder Bio- |
Schering-Plough Corp. |
Deal to use Alder technologies to identify and produce antibodies more rapidly and cost effectively |
Alder will work with up to 10 Schering-Plough products; Alder is eligible to receive milestone payments, research support and royalties on each of the antibodies (12/2) |
Alimentary |
Procter & Gamble Co. |
They entered a worldwide license agreement covering gastrointestinal indications |
Details on the deal were not disclosed; they are partners in the Alimentary Pharmabiotic Centre at University College Cork (12/14) |
Ambit |
Bristol-Myers Squibb Co. |
BMS gets access to kinase profiling technology for use in discovery and development, under a five-year expansion of an existing deal |
Ambit gets an up-front payment, an equity investment and profiling revenues over the five-year term; it also got rights to develop candidates from a cancer-directed preclinical kinase inhibitor program (12/12) |
Ambrx Inc.* |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal to use Ambrx technology to develop next-generation proteins and peptides |
The initial focus is on pegylated interferon- alpha molecules; Ambrx is entitled to license fees, research funding, milestone payments and royalties on sales (12/8) |
American |
Taiho Pharmaceutical Co. Ltd. (Japan) |
Taiho got rights in Japan to Abraxane, a taxane product for solid tumors |
APPI is entitled to up-front and milestone payments in excess of $50M, as well as royalties on sales; it also will supply product for the Japanese market (11/15) |
Apoxis SA* |
Astellas Pharma GmbH (Germany) |
Apoxis acquired worldwide rights to FK866, a cancer compound it renamed APO866 |
Phase II trials are planned; Astellas gets an up-front payment and potential milestone and royalty payments (12/15) |
Ardana plc |
Pharmacuro ApS (Denmark) |
Pharmacuro got rights to market Striant SR in the Nordic region |
Pharmacuro anticipates launching the testosterone replacement therapy in 2006; terms of the deal were not disclosed (11/9) |
Array |
Ono Pharmaceutical |
Collaboration to create small- molecule drug candidates against a series of kinases selected by Ono |
Ono will provide funding to access Array's Drug Discovery Platform; Array also is entitled to milestone payments, and royalties on any resulting sales (11/4) |
Astex |
Novartis AG (Switzerland) |
Novartis got rights to Astex's cell-cycle inhibitor AT9311, and an option to license the cell-cycle inhibitor AT7519 |
Astex gets up-front and deferred equity payments totaling $25M, and is entitled to research funding, reimbursement fees, option payments and milestones; total funding, excluding royalties, could reach $520M if three products are successfully developed (12/6) |
AtheroGenics |
AstraZeneca plc (UK) |
AstraZeneca got worldwide rights to AGI-1067, an AtheroGenics product in Phase III trials for treating atherosclerosis |
AtheroGenics gets $50M up front and up to $300M in regulatory and development milestones; it also is entitled to up to $650M in sales-related milestones, as well as royalties on sales(12/22) |
AVEO |
Merck & Co. Inc. |
Deal to use AVEO's platform to identify likely responders to cancer drugs being developed by Merck |
AVEO gets an equity investment, annual research funding and potential milestone payments; the deal involves use of AVEO's Human Response Prediction platform (11/2) |
Benitec Ltd. |
Sigma-Aldrich Corp. |
Sigma-Aldrich got an exclusive license to use Benitec's RNAi technology in the research reagent market |
Benitec received a $2M license payment, and received a $2.5M equity investment at A$0.17 per share; it also is entitled to revenue from royalties and sublicenses (10/24) |
BioCryst |
Hoffmann-La Roche Inc. |
Roche got exclusive rights to the Phase I compound BCX- 4208, which is being developed for transplantation and autoimmune indications |
BioCryst gets $25M up front and $5M for material; milestone payments could reach $530M; BioCryst would get royalties on any sales; BioCryst retains certain U.S. co-promotion rights (11/30) |
BioTrove Inc.* |
Schering-Plough Research Institute |
BioTrove will use its RapidFire Lead Discovery service on Schering-Plough targets |
BioTrove will provide assay development and high-throughput screening under the expansion of an existing agreement (12/6) |
Cambridge |
Genencor International Inc. (unit of Danisco A/S; Denmark) |
CAT acquired the Phase II cancer drug GCR-3888 and the preclinical cancer drug GCR-8015; it also hired 10 people involved in the program |
Genencor is getting $14M in the form of 1.17M CAT shares, or 2.3% of CAT; it could get another $2M in milestone payments (11/1) |
Caprion |
AstraZeneca plc (UK) |
Deal under which AstraZeneca will evaluate a number of prostate cancer drug targets discovered by Caprion |
Caprion gets an up-front payment and license fees, and could get development and commercialization milestone payments (11/1) |
Cardium |
Schering AG (Germany) |
Cardium acquired a portfolio of cardiovascular growth factor therapeutic candidates |
Terms of the deal were not disclosed; the deal was made concurrently with a merger and financing by Cardium (10/20) |
Cellectis SA* |
Shire Pharmaceuticals Group plc (UK) |
Shire got nonexclusive rights to site-directed genome engineering technologies |
The technology will be used to develop genetically engineered cells to produce certain gene-activated drugs; terms were not disclosed (12/20) |
Cellectis SA* |
AstraZeneca plc (UK) |
AstraZeneca got nonexclusive rights to use homologous recombination technology |
AstraZeneca got rights to use the technology for manipulations of genetic material in rodents; terms were not disclosed (12/13) |
Cenix |
Schering AG (Germany) |
They extend partnership in target validation following successful pilot phase |
Cenix will use its high-throughput RNAi technology in up to six more projects to screen genes identified by Schering; terms were not disclosed (10/25) |
Cephalon Inc. |
Bausch & Lomb Inc. |
B&L got rights to develop ophthalmic products containing products that inhibit angiogenesis |
B&L is responsible for development; Cephalon would get a milestone payment upon acceptance of a drug application and would get royalties on sales (12/1) |
Cerimon |
Undisclosed Japanese company |
Cerimon acquired U.S. rights to two topical formulations of diclofenac |
Diclofenac is a non-steroidal anti-inflammatory drug; terms of the deal were not disclosed (10/26) |
Corcept |
Eli Lilly and Co. |
Lilly will support Corcept's study of Corlux, a GR-II antagonist, to mitigate weight gain associated with use of olanzapine |
Lilly will supply olanzapine and pay for the study, which will explore the mechanism of action of GR-II antagonists for mitigating weight gain associated with atypical antipsychotic medications (10/21) |
Crucell NV |
Ferring Pharmaceuticals A/S(Denmark) |
Ferring got rights to use the PER.C6 cell line in production of a specific protein in the field of women's health |
Terms of the deal were not disclosed (12/21) |
Crucell NV |
DSM Biologics (the Netherlands) |
Agreement to expand development of their PER.C6 protein and monoclonal antibody licensing business |
They plan to develop an integrated solution for producing recombinant products on the cell line; they have been working together since 2002 (12/20) |
Crucell NV |
Tibotec Pharmaceuticals Ltd. (unit of Johnson & Johnson) |
Tibotec got nonexclusive rights to use the PER.C6 cell line for research in the field of virology |
Crucell is entitled to a license fee, annual maintenance fees and milestone payments; further terms were not disclosed (11/23) |
Curis Inc. |
Centocor Inc. (unit of Johnson & Johnson) |
Curis will perform screening and other work for Centocor's BMP- program |
Centocor previously licensed the bone morphogenetic pathway technology from Curis; Centocor has an option to license resulting products (12/15) |
Curis Inc. |
Wyeth |
Wyeth extended the research term on their collaboration by one year, through Feb. 9, 2007 |
The January 2004 deal focuses on Hedgehog agonists, primarily in neurology; Curis is entitled to additional research funding (11/21) |
Cytori |
Olympus Corp. |
They formed a 50-50 joint venture to develop systems for stem cell and regenerative cell therapies |
They intend to develop devices based on Cytori's Celution System; Olympus will contribute device technology and $30M to the venture; Cytori gets $11M up front and a potential $11M milestone payment (11/4) |
Depomed |
Madaus Srl (Italy) |
Madaus got exclusive rights to commercialize the antibiotic ProQuin XR in Europe |
Madaus is responsible for gaining approvals in Europe; specific terms were not disclosed (11/29) |
Discovery |
Chrysalis Technologies (unit of Philip Morris USA Inc.) |
Deal to develop and market aerosolized surfactant replacement therapies for treating respiratory conditions |
Discovery gets rights to Chrysalis' aerosolization technology for use with pulmonary surfactants; Chrysalis is entitled to royalties on resulting sales (12/11) |
Discovery |
Mitsubishi Pharma Corp. (Japan) |
Deal to discover lead compounds for a therapeutic target selected by Mitsubishi |
Terms and the therapeutic focus of the deal were not disclosed (10/26) |
Discovery |
Ono Pharmaceutical Co. Ltd. (Japan) |
DPI will work on multiple hit-to- lead and lead optimization projects for Ono |
Financial terms and the therapeutic focus were not disclosed (10/24) |
Domantis Ltd.* |
Bristol-Myers Squibb Co. |
Collaboration to develop Domain Antibody therapeutics in the fields of immunology and oncology |
Domantis gets $9.2M in up-front and research payments; it could get milestone payments of up to $20M per product, as well as royalties on sales; two existing Domantis programs are included (12/5) |
Evotec AG |
Boehringer Ingelheim GmbH (Germany) |
Evotec will work to identify promising hit molecules from each company's compound library |
The fee-for-services deal expands the scope of an existing collaboration; BI will develop any resulting compounds (11/3) |
Exelixis Inc. |
Wyeth |
Wyeth got rights to compounds targeting the farnesoid X |
Exelixis gets $10M up front and up to $147.5M in development and commercialization milestone payments, as well as royalties on any sales (12/22) |
Exelixis Inc. |
Bristol-Myers Squibb Co. |
Collaboration to develop therapies targeted against the liver X receptor, which is implicated in cardiovascular and metabolic disorders |
Exelixis gets $17.5M up front and could get development and regulatory milestones of $140M per product for up to two products; it also could get sales milestones and royalties on resulting sales (12/6) |
Genedata AG |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Multiyear expansion of their deal now includes all Roche high- throughput screening facilities in North America and Europe |
Roche will use Genedata Screener technology to estimate biological potency of compounds; terms were not disclosed (12/19) |
Gene Logic |
F. Hoffmann-La Roche Ltd. (Switzerland) |
Deal to reposition and develop multiple Roche drug candidates for which development had ended in Phase II or III trials |
Gene Logic can earn milestone and royalty payments on each candidate returned to clinical development; it also could license candidates not pursued by Roche (12/8) |
Genesis |
Harlan Bioproducts for Science Inc. |
Harlan will help develop monoclonal antibodies for use in the Mammastatin Serum Assay |
Harlan will work with Genesis subsidiary Biomedical Diagnostics LLC in the effort; terms were not disclosed (11/22) |
Gen-Probe |
BioMerieux SA (France) |
BioMerieux exercised a second option to develop diagnostic products using Gen-Probe's ribosomal RNA technologies |
The diagnostic focus was not disclosed; Gen-Probe gets a $2.1M license fee and would get royalties on resulting sales (12/22) |
GlycoFi Inc.* |
Merck & Co. Inc. |
Deal to apply GlycoFi's platform to produce and optimize a range of Merck's biologic drug candidates |
GlycoFi gets an up-front cash payment and equity investment, research funding and potential milestone and royalty payments (12/12) |
GTC |
LEO Pharma A/S (Denmark) |
LEO got rights to GTC's recombinant form of human antithrombin, ATryn, in Europe, the Middle East and Canada |
GTC gets $2M up front and is entitled to milestone payments of up to $71M, as well as royalties on any resulting sales (11/1) |
GW |
Almirall Prodesfarma SA (Spain) |
Almirall got rights to market Sativex in Europe (excluding the UK) |
GW gets £12M (US$21M) up front and up to £34M in milestone payments; the drug is in Phase III trials in three indications (12/12) |
Iconix |
Eli Lilly and Co. |
Lilly gained access to Iconix's chemogenomics technology |
Lilly will use the technology to prioritize and select drug candidates and to improve understanding of new compounds; terms of the deal were not disclosed (11/17) |
Incyte Corp. |
Pfizer Inc. |
Pfizer got exclusive rights to Incyte's CCR2 antagonist compounds, the most advanced of which is in Phase IIa trials |
Incyte gets $40M up front, research funding and will get $20M from the sale of interest-free convertible notes to Pfizer; it also could earn up to $743M in milestones, and royalties on sales; Incyte retains rights in multiple sclerosis and one undisclosed indication (11/21) |
InforSense |
AstraZeneca plc (UK) |
AstraZeneca got rights to InforSense technology through a new multiyear licensing deal |
AstraZeneca has been using the InforSense integrative analytics platforms since 2001; terms of the expanded deal were not disclosed (12/15) |
InterMune |
Valeant Pharmaceuticals International Inc. |
Valeant acquired U.S. and Canadian rights to the approved hepatitis C drug Infergen |
InterMune gets an up-front cash payment of $113.5M, about $2M in 2007, and up to $20M in milestone payments (11/28) |
Introgen |
Colgate-Palmolive Co. |
Deal to develop products to help prevent precancerous conditions of the oral cavity and oral cancer |
Introgen will focus on oral formulations of some of its therapeutics that use tumor suppressors; Colgate purchased $20M in Introgen stock for priority rights; further terms were not disclosed (11/7) |
Invitrogen |
Procter & Gamble Pharmaceuticals Inc. |
They extended an RNAi research service agreement through 2006 |
Invitrogen is using its technologies to help P&G's target identification and validation programs; terms were not disclosed (11/1) |
Jerini AG |
Kos Pharmaceuticals Inc. |
Deal for the development and marketing in North America of Jerini's Icatibant for hereditary angioedema and other diseases |
Jerini gets $15M up front and a $12M equity investment; it also is entitled to milestone payments and royalties on any resulting sales (11/7) |
Labopharm |
Recordati SpA (Italy) |
Recordati got exclusive rights to market Labopharm's once-daily tramadol product in the UK |
They anticipate launching the analgesic in the UK in 2006; Labopharm is entitled to an up-front payment, milestone payments and royalties on sales (11/16) |
LifeSpan |
Pfizer Inc. |
Pfizer gained access to all features of LifeSpan's DrugTarget Database |
As part of the deal Pfizer will nominate at least 60 new targets to be studied by immunohistochemistry and published in the consortium database (12/21) |
Maxygen Inc. |
Hoffmann-La Roche Inc. |
Deal to develop Maxygen's recombinant factor VIIa products for multiple indications |
They will share R&D costs; Maxygen retained certain commercialization rights; Maxygen could receive $95M in the deal, plus royalties on sales (12/15) |
MediGene |
Glaxo Group Ltd. (UK) |
Glaxo got nonexclusive rights to technology resulting from MediGene's program to develop a cancer vaccine |
MediGene gets an undisclosed one-time payment in the deal; specific technology details were not disclosed (12/19) |
MedImmune |
BioWa Inc. (unit of Kyowa Hakko Kogyo Co. Ltd.; Japan) |
MedImmune got rights to use Potelligent technology for enhancing antibody- dependent cellular cytotoxicity |
BioWa gets technology access fees, and could receive milestone payments and royalties on resulting products (12/7) |
Monogram |
Merck KGaA (Germany) |
Monogram will perform colorectal cancer biomarker studies for Merck |
The goal is to identify patients who most likely would benefit from Erbitux treatment; Monogram, formerly ViroLogic Inc., will receive undisclosed payments (10/24) |
MorphoSys |
Merck & Co. Inc. |
Merck got rights to use HuCAL GOLD and AutoCAL technologies for antibody development |
MorphoSys gets an up-front payment, annual user fees and R&D funding under the five-year license; it also could get license, milestone and royalty payments on resulting products (12/14) |
MorphoSys |
Bayer Pharmaceuticals Corp. |
Bayer gained access to the HuCAL GOLD antibody library under a five-year extension of their collaboration |
At least three new antibody development programs will be started in 2006, and up to 25 in all if the deal runs its full course; MorphoSys gets user fees, R&D funding and potential license, milestone and royalty payments (12/8) |
Myriad |
Abbott Laboratories |
They extended a collaboration in pharmacogenetics |
Abbott is funding work to identify genetic variation around drug targets in various stages of development (11/22) |
Neose |
Novo Nordisk A/S (Denmark) |
They expanded 2003 deal under which Novo is using Neose's GlycoPEGylation technology |
Novo is developing a next-generation version of a protein it markets; Neose is entitled to further R&D funding and an increased milestone potential (12/15) |
Nephrogen |
Gambro AB (Sweden) |
Collaboration focused on restoring kidney function using adult stem cells |
They initially will target acute renal failure in the three-year deal; terms were not disclosed (10/24) |
Neurome Inc.* |
Wyeth |
They expanded deal focused on drug discovery for neurodegenerative diseases |
Neurome now will evaluate drug candidates as part of intervention studies in an animal model; terms were not disclosed (11/21) |
NexMed Inc. |
Undisclosed Japanese company |
Agreement to develop a new fentanyl patch product for treating severe chronic pain |
NexMed got $0.1M up front and could get milestone payments; it retains certain commercialization rights (11/3) |
NicOx SA |
Pfizer Inc. |
Pfizer exercised its option to acquire exclusive rights to nitric oxide-donating compounds in ophthalmology |
NicOx received €2M, and potentially could receive €33M more, as well as royalties on any sales (11/22) |
NicOx SA |
Merck & Co. Inc. |
They extended August 2003 deal to evaluate NicOx nitric oxide-donating compounds in an undisclosed indication |
The deal also was broadened to an additional compound class; NicOx gets an undisclosed payment in connection with the deal's extension (11/2) |
Novation |
Novartis AG (Switzerland) |
Deal for the discovery of oral RNA-directed therapeutics |
Novation is providing use of its Quest assays in the deal; terms were not disclosed (11/23) |
OncoMethylome |
Schering-Plough Corp. |
Schering-Plough got rights to use assay technology that measures the methylation status of the MGMT gene |
The goal is to optimize Temodar therapy in treating patients with glioblastoma multiforme; OncoMethylome is entitled to an upfront fee, milestone payments and sample processing fees(11/16) |
OncoTherapy |
BioWa Inc. (subsidiary of Kyowa Hakko Kogyo Co Ltd.; Japan) |
Collaboration to identify and develop cancer-focused monoclonal antibodies |
They will carry out R&D collaboratively and would share any resulting profits (10/24) |
OSI |
Undisclosed British company |
The unnamed firm got nonexclusive rights from OSI's UK subsidiary relating to dipeptidyl peptidase IV patents |
The patents cover the use of DPIV inhibitors for treating Type II diabetes and related indications; OSI is entitled to up- ront, milestone and royalty payments (12/22) |
Oxford |
Undisclosed company |
The unnamed company got a license to OXB's LentiVector gene delivery system for research purposes |
Oxford BioMedica gets an up-front license payment and an annual maintenance fee; further terms were not disclosed (10/24) |
Oxford |
Sigma-Aldrich Corp. |
Deal under which Sigma- Aldrich will commercialize OXB's LentiVector technology for the reagent and research tool market |
Oxford BioMedica will receive an up-front payment, annual minimum payments and royalties on sales; it also will get a $5M equity investment; Sigma-Aldrich also gets first rights to develop products based on OXB's EIAV-based LentiVector technology (10/20) |
Oxford |
UCB Group SA (Belgium) |
UCB licensed rights to the Oxford Genome Anatomy Project database |
The database is used to discover and validate drug targets and biomarkers; terms of the deal were not disclosed (10/18)@ |
Pain |
King Pharmaceuticals Inc. |
Deal to develop and market PTI's Remoxy and other abuse-resistant opioid painkillers |
PTI gets $150M up front and up to $150M in milestone payments; King is expected to fund $100M of development costs; a pivotal trial of Remoxy (long-acting oxycodone) is expected to start in January (11/10) |
PPD Inc. |
Falco Biosystems Ltd. (Japan) |
PPD will seek to discover biomarkers for a renal cell carcinoma diagnostic test |
PPD will own resulting technology; Falco will get a license to resulting technology in certain countries; terms were not disclosed (12/7) |
Protein Design |
Hoffmann-La Roche Inc. |
Expanded deal to develop and sell daclizumab (Zenapax) for organ transplant patients now covers a subcutaneous formulation made by PDL |
PDL gets $10M up front and may be eligible for milestone payments of up to $145M; they will share development costs; PDL has a co-promotion option in the U.S. and would get royalties on sales elsewhere (11/1) |
Protherics plc |
AstraZeneca plc (UK) |
AstraZeneca got rights to the sepsis product CytoFab, which is nearing a Phase III trial |
Protherics gets £16.3M (US$29M) up front and a £7.5M equity investment; milestone payments could total £171M (US$304); Protherics would get royalties of 20% (12/8) |
pSivida Ltd. |
Beijing Med-Pharm Corp. |
Beijing Med-Pharm got rights to pSivida's BrachySil cancer product in China |
Beijing Med-Pharm will be responsible for development and marketing in China; terms were not disclosed (10/26) |
PTC |
Bausch & Lomb Inc. |
B&L got an option to exclusively license certain PTC compounds for use in ophthalmology indications |
The compounds are from PTC's anti-angiogenesis program; terms of the deal were not disclosed (12/1) |
Radius* |
Ipsen SA (France) |
Radius got worldwide rights except in Japan to BA058 and its analogues, along with rights to formulation technologies |
BA058 is an analogue of parathyroid hormone-related protein in Phase I trials for osteoporosis; Ipsen gets up-front and potential milestone and royalty payments (12/13) |
Regeneron |
Sanofi-Aventis Group (France) |
They broadened collaboration on the VEGF Trap program to include Japan; the deal now is worldwide, excluding intraocular delivery to the eye |
Regeneron gets $25M up front, as well as potential milestone and royalty payments under the expansion (12/22) |
Rubicon |
Abbott Laboratories |
Deal to develop and market Rubicon's MethylPlex methylation detection technology for diagnosis and prognosis of cancers |
Rubicon will work with Abbott Molecular in the multiyear deal, terms of which were not disclosed (10/31) |
Saneron CCEL |
GE Healthcare |
Collaboration on optimizing GE's Ficoll-Pacque for isolating stem cells from cord blood |
Terms of the deal were not disclosed (11/21) |
Sareum |
Schering AG (Germany) |
Sareum will use its technologies to show how drug candidates interact with their target protein receptors |
Sareum is entitled to receive research fees and potential milestone payments (10/27) |
Scolr Pharma |
Wyeth Consumer Healthcare |
Wyeth got rights to use Scolr's CDT delivery platform in an over-the-counter formulation |
Scolr gets an up-front licensing fee, and could get milestone and royalty payments (12/22) |
SkyePharma |
Maruho Co. Ltd. (Japan) |
Maruho got rights to develop and market the anesthetic DepoBupivacaine in Japan |
SkyePharma is entitled to up to $18M in up- front and milestone payments, as well as royalties on any resulting sales (11/1) |
Syntonix |
Boehringer Ingelheim GmbH (Germany) |
Deal to optimize certain BI peptides for inhalation, using Syntonix's SynFusion and Transceptor technologies |
Syntonix gets an up-front fee and research support, and could get milestone and royalty payments on any resulting products; the deal could be worth $63M (10/21) |
Theravance |
Astellas Pharma Inc. (Japan) |
Deal to develop and market Theravance's antibiotic telavancin, which is in Phase III trials |
Theravance gets $65M up front and up to $156M in clinical and regulatory milestone payments; it would get royalty rates ranging from the high-teens to the high-20s (11/7) |
TransTech |
Boehringer Ingelheim GmbH (Germany) |
BI got rights to develop compounds directed at an undisclosed target ofi interest to both companies |
TransTech gets an up-front payment, research support and potential milestone payments in a deal worth up to $54M; it also would get royalties on sales (12/21) |
Vernalis plc |
Mylan Laboratories Inc. |
Vernalis acquired North American rights to Apkyn, a marketed product for treating hypomobility |
The condition is associated with Parkinson's disease; Vernalis paid $23M in cash for the exclusive rights (11/4) |
Vernalis plc |
Britannia Pharmaceuticals Ltd. (UK) |
Deal to develop new formulations of apomorphine in North America for treating Parkinson's disease |
Vernalis got rights to use Britannia technology to develop a continuous subcutaneous infusion of apomorphine, and to negotiate a deal on a nasal powder formulation (11/4) |
Vertex |
GlaxoSmithKline plc (UK) |
GSK got rights to develop VX-409, a sodium channel modulator for treating pain, and backup compounds |
Vertex gets $20M up front and up to $385M in development and sales milestone payments, as well as royalties on any resulting sales (12/14) |
Xceleron Ltd.* |
Servier SA (France) |
Xceleron will provide accelerator mass spectrometry services to Servier |
The AMS technology will be used to help accelerate drug discovery and development; terms of the one-year deal were not disclosed (12/7) |
Xenogen Corp. |
Novartis AG (Switzerland) |
They extended for two years deal under which Novartis licensed Xenogen software |
Novartis will continue to use the Living Image Software and methods of biophotonic imaging; the original deal was signed in 2000 (12/7) |
XenoPort Inc. |
Astellas Pharma Inc. (Japan) |
Astellas got rights in Japan and elsewhere in Asia to the Phase II CNS agent XP13512, a prodrug of gabapentin |
XenoPort gets a license payment of $25M and could get up to $60M in milestone payments, as well as mid-teen royalty rates on product sales in the territory (11/30) |
YM BioSciences |
Innogene Kalbiotech Ltd. (Singapore) |
Innogene, a unit of PT Kalbe Farma Tbk, got certain right to the EGFR- targeting monoclonal antibody nimotuzumab |
YM subsidiary CimYM gets $1M up front and potential milestone and royalty payments; Innogene gets rights in Singapore, Taiwan, Thailand, Indonesia, Malaysia, the Philippines, South Africa and other markets (11/17) |
Znomics Inc.* |
Merck & Co. Inc. |
Deal to discover and characterize drug targets for metabolic diseases |
They will use Znomics' zebrafish technology in the deal, terms of which were not disclosed (12/5) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
@ News occurred before the time frame of this chart but was not included in the previous chart. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AIM = Alternative Investment Market; AMEX = American Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.